Haystack MRD Test
Accelerate clinical development with better MRD testing
Unmatched sensitivity and specificity for confident MRD detection. Interested in learning more about how Haystack MRD can support your clinical trials?
Quick View
Haystack MRD Test
Haystack MRD™ is a tumor-informed liquid biopsy test that begins with tissue-based whole exome sequencing (WES) to identify patient-specific tumor mutations. A personalized MRD test is then developed to detect ctDNA from residual, recurrent, or resistant disease.

Click to enlarge
Analytical performance details
Confident MRD calls
Haystack MRD delivers exceptional accuracy at ultra-low ctDNA levels. The test's clean background allows the calling threshold to be set lower than other methods, which yields the highest sensitivity for patient enrollment, stratification, and response monitoring.

Click to enlarge
The multi-tool of MRD
Unlike other tests, Haystack MRD was purpose-built for granular ctDNA testing that reports variant-level results. In addition to reporting sample-level MRD status, Haystack MRD can track specific ctDNA variants for various applications, including targeted therapy guidance.
Each patient’s whole genome library is also archived and is available for acquired resistance mapping and retrospective genomic discovery.

Click to enlarge


Contact Us
Get in touch
With our deep roots in liquid biopsy and MRD testing, Haystack Oncology is committed to providing biopharma solutions to improve patient outcomes. Let our unmatched MRD detection capabilities and team of global experts support your clinical cancer research and therapeutic development efforts.
Have questions? We would love to hear from you. Simply click the button below.